Namenda to Prevent Post-Operative Delirium

• Status: Terminated
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge.

Namenda, which is currently approved for moderate or severe Alzheimer's disease has a unique mechanism of action than other drugs for this condition. It may have the ability to protect the brain from more severe consequences of hypoxia, or hypoglycemia. Hence it is being looked at in this study to see if it can reduce the incidence and/or severity of delirium post-operatively.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester
• Collaborator: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Medically stable

• 50 years of age or older

• having elective joint replacement surgery or other orthopedic procedures that are major surgery and require general anesthesia.

Exclusion Criteria:

• Alcohol or sedative hypnotic abuse or dependence

• Pregnancy

• Dementia or MR/DD patients if they do not have sufficient capacity to understand the consent

• renal impairment or a creatinine of 1.4 or higher

• currently taking cholinesterase inhibitors.